Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. (VTAK) is a U.S.-based medical device company focused on the cardiac electrophysiology market, and its news flow reflects developments around its VIVO 3D imaging system and LockeT suture retention device. The company’s releases highlight product adoption, regulatory milestones, financial updates, and corporate actions relevant to investors and clinicians following VTAK stock.
Recent news has emphasized international expansion for both VIVO and LockeT. Catheter Precision has reported tender wins and first purchase orders for the VIVO system at hospitals such as Albert Szent‑Györgyi Health Centre in Hungary and Dubrava University Hospital in Croatia, following evaluations against competing technologies. For LockeT, the company has announced launches in Switzerland and South Africa, distribution agreements with regional partners, and implementation at major electrophysiology centers, including Mater Private Hospital in Dublin, Ireland.
In addition to commercial updates, Catheter Precision issues releases on financial results, furnished on Form 8‑K, summarizing revenue trends and operating performance for specific quarters and year‑to‑date periods. The company also uses news announcements to discuss regulatory and reimbursement developments that may affect the use of its products, such as changes in procedure coverage for ambulatory surgery centers that it views as relevant to LockeT utilization.
Other news items cover intellectual property developments, including allowance of patents related to ventricular arrhythmia localization and neurostimulation devices, as well as corporate and capital markets events like reverse stock splits, at‑the‑market offering programs, and stockholder meetings. For ongoing insight into VTAK, this news page aggregates these updates so readers can follow Catheter Precision’s product adoption, geographic reach, financial disclosures, and key regulatory or governance events over time.
Catheter Precision (NYSE:VTAK) will attend the 47th Heart Rhythm Society meeting in Chicago, April 24–27, 2026, featuring the VIVO system in a poster (April 24) and a core-session presentation (April 25). Two new peer‑reviewed papers for LockeT (139 patients) and VIVO (31 patients, 48 VTs) are published online.
The announcements emphasize feasibility data for intracardiac VT localization, workflow benefits for VT ablation, and LockeT venous‑closure outcomes including high procedural success and low complication rates.
Catheter Precision (NYSE American: VTAK) received a Notice of Allowance from the USPTO on April 21, 2026, for key claims covering its LockeT surgical vessel closing pressure device.
The allowed claims protect both the device architecture and method of use, reinforcing the company’s intellectual property position, creating barriers to entry, and supporting its IP-driven commercialization and growth strategy.
Flyte (NYSE American: VTAK) said it is accelerating expansion in short‑haul regional markets on April 20, 2026, as major airlines cut routes amid rising jet fuel costs and network redeployment. Flyte operates FAA Part 135 service with Cirrus Vision Jets and reports active, revenue‑generating operations to capture displaced demand.
The company positions point‑to‑point, right‑sized flights as a lower‑fuel, high‑frequency alternative in underserved corridors, notably in the Northeast, where airline service is declining.
Catheter Precision (NYSE: VTAK) completed a shareholder-approved acquisition of Fly Flyte on April 15, 2026, making Flyte a wholly owned operating subsidiary. The deal immediately consolidates 100% of Flyte’s revenue, assets, and operations into VTAK and provides direct exposure to cash flow from FAA Part 135 certified regional air services.
The acquisition gives VTAK control of capital allocation, fleet expansion, and a revenue-generating aviation platform positioned for scalable growth in regional air mobility ahead of eVTOL commercialization.
Catheter Precision (NYSE American: VTAK) announced that a VIVO study has been accepted for publication in EP Europace on April 13, 2026. The 31‑patient study mapped 48 VTs and found ECGi mapping with VIVO accurately predicted arrhythmogenic substrate for scar‑dependent VT and may improve procedural efficiency.
The study reported VIVO localization in NICM patients showed 100% specificity and 66.7% sensitivity for epicardial VTs versus a four‑step ECG algorithm (sensitivity 50%, specificity 0%). The company plans a larger multi‑center study later in 2026.
Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. The company said it will use the event to share new data, engage key opinion leaders and educate physicians and distributors about LockeT after CE Mark receipt.
This appearance is the company's first large European conference since LockeT received CE Mark clearance and aims to support expanded product use and commercial momentum.
Catheter Precision (NYSE American: VTAK) announced acceptance of a manuscript in the Journal of Interventional Cardiac Electrophysiology on April 6, 2026. The study of LockeT in 139 patients reported high procedural success, rapid hemostasis, early ambulation, and low complication rates for large-bore venous access closure.
The peer-reviewed acceptance supports LockeT as a feasible venous closure strategy in electrophysiology practice and may aid the company’s commercialization and hospital engagement efforts in the US and Europe.
Catheter Precision (NYSE American: VTAK) engaged a strategic advisor on April 2, 2026 to formally market for sale its cardiac electrophysiology business. The process aims to monetize legacy medical device assets (LockeT and VIVO) that have FDA market clearance and the CE mark, while the company sharpens focus on its Flyte aviation platform. Management says the sale could unlock shareholder value and that monetization would position the company as a pure‑play aviation business through disciplined capital allocation and increased execution and transparency.
Catheter Precision (NYSE American: VTAK) reported full-year 2025 results and described a strategic expansion. Key 2025 metrics: revenue $819 thousand (+95% YoY), gross margin 92.3%, and net loss $17.2 million (including $7.8 million non-cash).
Post-year-end the company acquired Flyte, a revenue-generating regional air mobility operator, and completed financings to strengthen capital for a dual-platform strategy across medical devices and aviation.
Catheter Precision (NYSE American: VTAK) subsidiary Fly Flyte announced expansion of its Vision Jet-powered Hops short‑haul regional platform, operating three aircraft today with two additional Vision Jets under accepted bids and expected to be fully operational by Memorial Day 2026.
The Hops model targets flights under ~500 miles, offering private‑terminal access, rapid booking‑to‑boarding, AI-driven scheduling/pricing, right‑sized economics, and safety features (CAPS, Safe Return) to enable high‑frequency regional travel.